This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Sun Pharmaceutical Industries and Philogen S.p.A. have completed patient enrollment in the Phase III FIBROSARC trial for Soft Tissue Sarcoma (STS). All ongoing trials for Fibromun, an investigational biopharmaceutical product, remain on track with their expected timelines. Dario Neri, CEO of Philogen, stated, We are highly encouraged by the progress of Fibromuns pivotal trials in both soft tissue sarcoma and glioblastoma.
In this episode, I’ll discuss whether delayed broad-spectrum antibiotics have an impact on clinical outcomes. Episode 999: Is This Study a Breakthrough for Antimicrobial Stewardship? Subscribe on iTunes , Android , or Stitcher From my experience with antimicrobial stewardship efforts, the biggest reason for overly broad antibiotic coverage is what I call the “what if” factor.
Alkem Laboratories, an Indian pharmaceutical company, has announced two strategic acquisitions aimed at strengthening its position in the domestic market. The company has signed a binding term sheet to acquire a 100 per cent stake in Adroit Biomed, a company focused on the skincare segment, for approximately INR 140 crore. In addition, Alkems subsidiary, Alkem MedTech, has entered a binding offer to acquire a 100 per cent stake in Bombay Ortho Industries, a manufacturer of orthopaedic implants,
Survey results show that being intellectually stimulated and getting assigned challenging projects are two key drivers of employee satisfaction, yet job training is lacking.
Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.
Billions in EU Covid funding have gone unaccounted for. By hiding its business behind personal messaging, Brussels is dodging public scrutiny For weeks during the height of the Covid pandemic in early 2021, the European Commission president, Ursula von der Leyen, personally exchanged calls and texts with Albert Bourla, the CEO of the pharmaceutical company Pfizer.
Billions in EU Covid funding have gone unaccounted for. By hiding its business behind personal messaging, Brussels is dodging public scrutiny For weeks during the height of the Covid pandemic in early 2021, the European Commission president, Ursula von der Leyen, personally exchanged calls and texts with Albert Bourla, the CEO of the pharmaceutical company Pfizer.
Molly Schiffer, PharmD, BCOP, discusses the logistical and operational challenges of delivering outpatient CAR T-cell therapy, emphasizing the benefits of outpatient treatment, including reduced costs, improved access to therapy, and better quality of life for patients.
Top universities and medical centers stand to lose $100 million a year or more if a sweeping change to how the National Institutes of Health reimburses research costs takes effect on Monday. The big losers would include prestigious institutions in conservative states. NIH, the nation’s top funder of biomedical research, announced on Friday that it would substantially limit payments for indirect costs, administrative and facility expenses connected to research, starting almost immedi
February 05, 2025: “The U.S. Food and Drug Administration is alerting patients of a safety concern regarding diabetes devices, such as continuous glucose monitors (CGMs), insulin pumps and automated insulin dosing systems, that rely on a smartphone to deliver critical safety alerts. Users of these smartphone-compatible diabetes devices can configure alert settings, such as which alerts to receive, how often and how the alerts are delivered (e.g. audible, vibration, text only) through the a
In this episode, I’ll discuss whether delayed broad-spectrum antibiotics have an impact on clinical outcomes. Episode 999: Is This Study a Breakthrough for Antimicrobial Stewardship? Subscribe on iTunes , Android , or Stitcher From my experience with antimicrobial stewardship efforts, the biggest reason for overly broad antibiotic coverage is what I call the “what if” factor.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
This video is part of a three-part series covering new literature that could influence clinical practice. In this video, I discuss whether beta-blocker use post-MI is beneficial for patients with HFpEF. Background about the mechanism of action and typical place in therapy leads into background studies leading to the current research. Finally, the REDUCE-AMI study […] The post Beta-Blockers After MI and Use In HFpEF appeared first on Med Ed 101.
Introduction The term "surfactant" is a contraction of "surface active agent". Surfactants reduce the surface tension between two ingredients (or phrases) in a preparation to make them more miscible (easier to mix together). Their amphiphilic nature - possessing both hydrophilic (water-loving) and hydrophobic (water-fearing, lipid loving) components - allows them to interact with diverse substances.
Biomedical researchers in Massachusetts braced this weekend for drastic and sudden federal funding cuts which local officials say will upend scientific endeavors at universities and medical centers synonymous with the state’s reputation and economy. The change — announced by Republican President Trump’s administration on Friday and set to take effect Monday — caps reimbursement rates from the National Institutes of Health at 15 percent for expenses that support resear
Introduction A unit-dose medication distribution system uses medications packaged in unit-dose or single-unit packages. A single-unit package contains one dosage form of medication (e.g., one capsule, one 5 ml volume of liquid, etc.). A unit-dose package contains the dose of a medication ordered for a patient (e.g. two 250 mg tablets for a 500 mg dose).
Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.
Introduction Good Compounding Practice, 2018 stipulates that compounding documents should include Master formulas Compounding records Standard operating procedures (SOPs) and related records Records such as the Certificate of Analysis (COA) and Material Safety Data Sheet (MSDS) for all ingredients All records and reports should be retained for 1 year after the beyond-use date, in accordance with relevant laws.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
66 
Let's personalize your content